Amgen rises after autoimmune drug meets late-stage trial goal
22/09/2026 14:48
BUZZ-Amgen rises after autoimmune drug meets late-stage trial goal ** Shares of drugmaker Amgen AMGN.O rise 2.4% to $402.69
** Co says its experimental drug, dazodalibep, for Sjogren's disease met the main goal of reducing disease activity in a late-stage trial
** Sjogren's disease is an autoimmune disorder that causes dryness of the eyes, mouth and other parts of the body, along with fatigue and chronic pain
** Drug showed a statistically significant and clinically meaningful improvement at week 48; most side effects were mild to moderate
** Co plans to present detailed results at an upcoming medical meeting
** Including session's move, AMGN up 23.1% YTD
(Reporting by Kunal Das in Bengaluru)
Recent news on Amgen
See all newsUS RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally